Announcing a new publication for Acta Materia Medica journal. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since 2020. The nucleocapsid (N) protein plays a crucial role in the life cycle of SARS-CoV-2. The authors of this article have established a method to screen inhibitors of N protein by using microscale thermophoresis assays to obtain potential anti-SARS-CoV-2 agents. 1,7-bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one (N-17, a diphenylheptane) was identified as a compound with outstanding inhibitory activity. The binding of N-17 to the N-terminal domain of N protein (N-NTD) was further validated by using drug affinity responsive target stability assays. The ability of N-17 to bind N protein was evaluated and the affinity of N-17 to the N-NTD with molecular docking and molecular dynamics simulation was predicted. N-17 exhibited excellent anti-viral activity against HCoV-OC43 and SARS-CoV-2, with EC50 values of 0.16 ± 0.01 μM and 0.17 ± 0.07 μM, respectively. Thus, a novel SARS-CoV-2 inhibitor targeting the N protein was discovered and its anti-viral activity in vitro was validated. The results may contribute to the development of promising therapeutic agents for COVID-19
Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.
Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/ammed
Queries about the journal can be sent to firstname.lastname@example.org.
Please visit https://amm-journal.org/ to learn more about the journal.
Editorial Board: https://amm-journal.org/index.php/editorial-board/
There are no author submission or article processing fees.
Yang Liu, Kuiru Sa and Wei Xu et al. 1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one inhibits SARS-CoV-2 by targeting the nucleocapsid protein. Acta Materia Medica. 2023. Vol. 2(3):270-280. DOI: 10.15212/AMM-2023-0021